Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Gefitinib vs Gefitinib in EGFR+ NSCLC
NCT01469000Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Feb 2012; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01469000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01469000.